The Journal of Pediatrics
Volume 156, Issue 2 , Pages 197-201.e1 , February 2010

Efficacy of Local Instillation of Recombinant Tissue Plasminogen Activator for Restoring Occluded Central Venous Catheters in Neonates

  • Hanifi Soylu, MD

      Affiliations

    • Division of Neonatology, Department of Pediatrics, University of Toronto, Ontario, Canada
    • ,
  • Leonardo R. Brandão, MD

      Affiliations

    • Division of Hematology/Oncology, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada
    • ,
  • Kyong-Soon Lee, MD, FRCP, MSc

      Affiliations

    • Division of Neonatology, Department of Pediatrics, University of Toronto, Ontario, Canada
    • Corresponding Author InformationReprints not available. Correspondence to Dr Kyong-Soon Lee, Division of Neonatology, Room 38102, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8.

Received 1 March 2009 ,Revised 6 July 2009 ,Accepted 2 September 2009.

References 

  1. Haas NA, Haas SA. Central venous catheter techniques in infants and children. Curr Opin Anaesthesiol. 2003;16:291–303
  2. Ainsworth SB, Clerihew L, McGuire W. Percutaneous central venous catheters versus peripheral cannulae for delivery of parenteral nutrition in neonates. Cochrane Database Syst Rev. 2007;3:CD004219
  3. Hermansen MC, Hermansen MG. Intravascular catheter complications in the neonatal intensive care unit. Clin Perinatol. 2005;32:141–156
  4. Paulson PR, Miller KM. Neonatal peripherally inserted central catheters: recommendations for prevention of insertion and postinsertion complications. Neonatal Netw. 2008;27:245–257
  5. Beardsall K, White DK, Pinto EM, Kelsall AW. Pericardial effusion and cardiac tamponade as complications of neonatal long lines: are they really a problem?. Arch Dis Child Fetal Neonatal Ed. 2003;88:F292–F295
  6. Benjamin DK, Miller W, Garges H, Benjamin DK, McKinney RE, Cotton M, et al. Bacteremia, central catheters, and neonates: when to pull the line. Pediatrics. 2001;107:1272–1276
  7. Monagle P, Chalmers E, Chan A, deVeber G, Kirkham F, Massicotte P, et al. Antithrombotic therapy in neonates and children. Chest. 2008;133:887S–968S
  8. Important drug warning regarding the use of Abbokinase (urokinase). Rockville, MD: US Food and Drug Administration, Center for Drug Evaluation and Research; 1999;208-1448
  9. Hartmann J, Hussein A, Trowitzsch E, Becker J, Hennecke KH. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature. Arch Dis Child Fetal Neonatal Ed. 2001;85:F18–F22
  10. Atkinson JB, Bagnall HA, Gomperts E. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters. JPEN J Parenter Enteral Nutr. 1990;14:310–311
  11. Gupta AA, Leaker M, Andrew M, Massicotte P, Liu L, Benson LN, et al. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr. 2001;139:682–688
  12. Levy M, Benson LN, Burrows PE, Bentur Y, Strong DK, Smith J, et al. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr. 1991;118:467–472
  13. Davis SN, Vermeulen L, Banton J, Schwartz BS, Williams EC. Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices. Am J Health Syst Pharm. 2000;57:1039–1045
  14. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation. 1997;96:761–768
  15. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER. COOL Investigators. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial: the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol. 2001;12:951–955
  16. Semba CP, Deitcher SR, Li X, Resnansky L, Tu T, McCluskey ER. Cardiovascular Thrombolytic to Open Occluded Lines Investigators. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients. J Vasc Interv Radiol. 2002;13:1199–1205
  17. Blaney M, Shen V, Kerner J, Jacobs BR, Gray S, Armfield J, et al. CAPS Investigators. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (the Cathflo Activase Pediatric Study). J Vasc Interv Radiol. 2006;17:1745–1751
  18. Shen V, Li X, Murdock M, Resnansky L, McCluskey ER, Semba CP. COOL Investigators. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Hematol Oncol. 2003;25:38–45
  19. Kleta R, Schleef J, Jürgens H. Tissue plasminogen activator and obstructed central venous catheters. Med Pediatr Oncol. 1998;30:376
  20. Choi M, Massicotte MP, Marzinotto V, Chan AK, Holmes JL, Andrew M. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J Pediatr. 2001;139:152–156
  21. Jacobs BR, Haygood M, Hingl J. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. J Pediatr. 2001;139:593–596
  22. Chesler L, Feusner JH. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters. J Pediatr Hematol Oncol. 2002;24:653–656
  23. Fisher AA, Deffenbaugh C, Poole RL, Garcia M, Kerner JA. The use of alteplase for restoring patency to occluded central venous access devices in infants and children. J Infus Nurs. 2004;27:171–174
  24. Ng R, Li X, Tu T, Semba CP. Alteplase for treatment of occluded peripherally inserted central catheters: safety and efficacy in 240 patients. J Vasc Interv Radiol. 2004;15:45–49
  25. Zenz W, Arl F, Sodia S, Berghold A. Intracerebral hemorrhage during fibrinolytic therapy in children: a review of the literature of the last thirty years. Semin Thromb Hemost. 1997;23:321–332
  26. Parmar N, Mitchell LG, Berry LR, Andrew M, Chan AKC. The influence of age on in vitro plasmin generation in the presence of fibrin monomer. Acta Haematol. 2006;115:141–151
  27. Lee EK. Alteplase use for prevention of central line occlusion in a preterm infant. Ann Pharmacother. 2002;36:272–274
  28. Mehta S, Connors AF, Danish EH, Grisoni E. Incidence of thrombosis during central venous catheterization of newborns: a prospective study. J Pediatr Surg. 1992;27:18–22
  29. Schiff DE, Stonestreet BS. Central venous catheters in low birth weight infants: incidence of related complications. J Perinatol. 1993;13:153–158
  30. Clinicath PolyFlow Polyurethane Peripherally Inserted Catheter. Instructions for use. Smiths Medical MD, Inc St Paul, MN. 2007.
  31. Kerner JA, Garcia-Careaga MG, Fisher AA, Poole RL. Treatment of catheter occlusion in pediatric patients. JPEN J Parenter Enteral Nutr. 2006;30:S73–S81
  32. Wang M, Hays T, Balasa V, Bagatell R, Gruppo R, Grabowski EF, et al. Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol. 2003;25:379–386

 The authors declare no conflicts of interest.

PII: S0022-3476(09)00875-0

doi: 10.1016/j.jpeds.2009.09.007

The Journal of Pediatrics
Volume 156, Issue 2 , Pages 197-201.e1 , February 2010

Article Tools

* Image Usage & Resolution